Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Effects on mitral and tricuspid valve regurgitation after 6 months of treatment with SGLT2 inhibitors in patients with chronic heart failure

Title: Effects on mitral and tricuspid valve regurgitation after 6 months of treatment with SGLT2 inhibitors in patients with chronic heart failure
Authors: Basile, P; Antonica, C; Falagario, A; Dicorato, M M; Monitillo, F; Santoro, D; Carella, M C; Dentamaro, I; Moretti, A; Falco, G; Amodio, N; Santobuono, V E; Forleo, C; Ciccone, M M; Guaricci, A I
Contributors: Basile, P; Antonica, C; Falagario, A; Dicorato, M M; Monitillo, F; Santoro, D; Carella, M C; Dentamaro, I; Moretti, A; Falco, G; Amodio, N; Santobuono, V E; Forleo, C; Ciccone, M M; Guaricci, A I
Publication Year: 2025
Collection: Università degli Studi di Bari Aldo Moro: CINECA IRIS
Subject Terms: Congenital Heart Disease; Valvular Heart Disease,Treatment Pharmacotherapy
Description: Background: Sodium-GLucose coTransporter 2 inhibitors (SGLT2i) have revolutionized the therapeutic management of chronic heart failure (CHF) with a remarkable reduction of mortality and an improvement of quality of life. Moreover, it was highlighted their bene cial role on adverse cardiac remodelling. The effects on mitral and tricuspid valve function of these drugs should be further explored. Purpose: The aim of this study was the investigation of the effects on mitral and tricuspid valve function after 6 months of treatment with SGL2i in patients with CHF. Methods: We conducted an observational, perspective, monocentric study enrolling 169 patients with CHF from December 2020 to March 2024 in a tertiary referral hospital. For each patient, anamnestic, laboratory, clinical and echocardiographic data were collected. Each patient underwent a transthoracic echocardiographic evaluation before SGLT2i initiation and after 6 months of follow-up by two cardiologists with expertise. The prescription of SGLT2i was made according to the European guidelines on Heart Failure. The examination was focused on the assessment of mitral and tricuspid valve regurgitations using a semi-quantitative rating scale and biventricular volumes and function. Results: The median age of the study population was 66 years (IQR 17) with a clear prevalence of male sex (82% of cases). More than 70% of subjects presented a dilated left ventricular (LV) phenotype, with an ischaemic aetiology in more than one third of cases. After 6 months of treatment was found a statistically signi cant reduction of Body Mass Index (p
Document Type: article in journal/newspaper
Language: English
Relation: info:eu-repo/semantics/altIdentifier/wos/WOS:001675680700001; volume:46; issue:Supplement_1; journal:EUROPEAN HEART JOURNAL; https://hdl.handle.net/11586/572463
DOI: 10.1093/eurheartj/ehaf784.2358
Availability: https://hdl.handle.net/11586/572463; https://doi.org/10.1093/eurheartj/ehaf784.2358
Accession Number: edsbas.E9C4E8A
Database: BASE